Peter Meyer, Christine Zuern, Norbert Hermanns and Thomas Haak wrote an interesting post today on
Here’s a quick excerpt
… to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM). …

Read the rest of this great post here